TNFRSF1B and acute myeloid leukemia: Treating AML patients with azacitidine and lenalidomide, a thalidomide derivative, can reduce TNFR2 expression on T cells, as well as the number of TNFR2+ Tregs, in vivo, leading to enhanced effector immune function (Govindaraj et al., 2014a).